Skip to content
Life Sciences Series D Founded 2014

Cykinso

Direct-to-consumer tests for intestinal microbiome profiling. Its flagship product Mykinso uses next-generation sequencing and proprietary bioinformatics for metagenomic profiling of the customer's stool sample. Users can purchase the fecal sample kit, register it online and mail the sample to the company. In addition, they are encouraged to fill in a lifestyle-related questionnaire that Cykinso plans to use in…

📍 Shibuya, Japan · Genomics,

Funding snapshot

Last roundSeries D
Amount$16M
Date22 April 2026
Total raised$16M

About

Direct-to-consumer tests for intestinal microbiome profiling. Its flagship product Mykinso uses next-generation sequencing and proprietary bioinformatics for metagenomic profiling of the customer's stool sample. Users can purchase the fecal sample kit, register it online and mail the sample to the company. In addition, they are encouraged to fill in a lifestyle-related questionnaire that Cykinso plans to use in future research. Results can be viewed on the company website or the accompanying app Founded in 2014, headquartered in Shibuya, Japan. The company has raised $15.7M at the Series D stage backed by investors including Nitto Boseki, Nihonkai, REVIC, Innoh Associates, Yamanashi Chugin Management Consulting. Operating in Life Sciences > Genomics, Life Sciences > Clinical Genomics.

Business model

Genomics > Applied Genomics > Consumer Genomics > Microbiomics

Institutional investors

Nitto Boseki Nihonkai REVIC Innoh Associates Yamanashi Chugin Management Consulting Akigin Capital Partners

Latest coverage

No articles yet.

Raising like Cykinso?

Analyze your pitch deck before your next raise.

Analyze My Deck →